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OBJECTIVES The primary objective of this research was to assess the activation level of circulating
monocytes in patients with unstable angina.
BACKGROUND Markers of systemic inflammatory responses are increased in patients with unstable coronary
syndromes, but the activation state and invasive capacity of circulating monocytes have not
been directly assessed.
METHODS Peripheral blood mononuclear cell (MC) activation in blood samples isolated from patients
with stable and unstable coronary artery disease was measured in two studies. In study 1, a
modified Boyden chamber assay was used to assess spontaneous cellular migration rates. In
study 2, optical analysis of MC membrane fluidity was correlated with soluble CD14
(sCD14), a cellular activation marker.
RESULTS Increased rates of spontaneous monocyte migration (p 0.01) were detected in patients with
unstable angina (UA) (Canadian Cardiovascular Society [CCS] angina class IV) on
comparison to patients with acute myocardial infarction (MI), stable angina (CCS angina
classes I to III) or normal donors. No significant increase in lymphocyte migration was
detected in any patient category. Baseline MC membrane fluidity measurements and sCD14
levels in patients with CCS class IV angina were significantly increased on comparison with
MCs from normal volunteers (p  0.001). A concomitant reduction in the MC response to
activation was detected (p  0.05).
CONCLUSIONS Using two complementary assays, activated monocytes with increased invasive capacity were
detected in the circulation of patients with unstable angina. This is the first demonstration of
increased monocyte invasive potential in unstable patients, raising the issue that systemic
inflammation may both reflect and potentially drive plaque instability. (J Am Coll Cardiol
2001;38:1340–7) © 2001 by the American College of Cardiology
Monocytes are present in all stages of atherogenesis, poten-
tiating inflammatory responses during early plaque develop-
ment and initiating breakdown and rupture of the fibrous
cap (1,2). The exposed lipid core of an unstable plaque is
highly thrombogenic, producing acute vascular occlusions
that result in myocardial infarction (MI) and unstable
angina (UA). Increased adhesion and invasion of monocytes
at sites of unstable plaque development have been demon-
strated on histological sections in many prior reports (1–6).
Significant increases in circulating serum markers of
monocyte (7–14) and T-cell (13–18) activation in patients
with UA and MI have been detected. Although local
monocyte activation inside the atherosclerotic plaque acts as
a focus for inflammation, cellular activation that occurs
while cells are still within the general circulation may also,
theoretically, contribute to unstable plaque formation. Ele-
vated levels of serum markers of inflammation (7,9,10),
specifically C-reactive protein (CRP) (9,10,19,20), serum
amyloid A (SAA) (20,21), CD11b/CD18 adhesion mole-
cules (22,23), interleukin-1 (IL-1), IL-6 (24), IL-8
(24,25) and macrophage chemoattractant protein (MCP-1)
(26), as well as increased levels of circulating leukocyte
aggregates (11) and increased monocyte cellular (MCP-1,
IL-1 and IL-8) messenger ribonucleic acid levels (18),
have been reported. Whether this increase in circulating cell
activation markers reflects an increase in the generalized
activation state and invasive capacity of monocytes in the
blood remains unproved.
We have measured activation of circulating peripheral
blood mononuclear cells (MCs) in two independent studies.
In the first study (study 1), the rate of spontaneous migra-
tion of MC isolated from peripheral blood samples was
assessed as a marker for a generalized increase in cellular
activation and invasive capacity in patients with varying
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degrees of coronary artery disease (CAD) (27). In the
second study (study 2), the membrane fluidity of MCs was
analyzed as a marker for cellular activation in patients with
varying extents of CAD and correlated with levels of serum
markers. Preceding the activation of cellular functions such
as migration or tissue invasion, cells rearrange their surface
membrane components. With this rearrangement, there is
an associated change in membrane fluidity. Prior studies
have demonstrated that membrane fluidity is a marker for
cellular activation in platelets (28,29), endothelial cells (30),
T cells (31) and epithelial cells (32), and altered membrane
fluidity has also been reported to correlate well with clinical
conditions such as diabetes (33) and Alzheimer’s disease
(34).
METHODS
Patient selection and stratification. Patients over 18 years
of age admitted for cardiac catheterization and capable of
informed consent were considered eligible. The MC migra-
tion was assessed in 29 subjects (study 1) and membrane
fluidity was assessed in 31 subjects (study 2). Mononuclear
cells were also isolated from normal volunteers (14 for study
1 and 17 for study 2). Both study groups were stratified
according to guidelines established by the Canadian Car-
diovascular Society (CCS) for symptomatic angina (35).
This investigation conforms to the principles outlined in the
Declaration of Helsinki, and all studies were approved by
the London Health Sciences Centre, University Hospital
(London, Ontario, Canada) and the University of Alberta
Hospitals (Edmonton, Alberta, Canada) ethical review
boards.
MC isolation. For patients, blood samples were taken
from the femoral arterial sheath during cardiac catheteriza-
tion before injection of contrast or additional medication.
Blood was taken up into ethylenediamine tetra-acetic acid
containing Vacutainer tubes (Beckton Dickinson and Col-
laborative Biomedical Products, Bedford, Massachusetts).
Blood samples from normal volunteers were drawn via
antecubital venous puncture. All blood samples were diluted
1:1 in phosphate-buffered saline (PBS; 8.4 mmol/l
Na2HPO4, 1.9 mmol/l NaH2PO4, 0.15 mol/l NaCl, pH
7.4) and layered over Ficoll-Paque Plus (Pharmacia Biotech,
Uppsala, Sweden). For MC migration assays, gradients
were centrifuged in a Beckman GS-15R centrifuge (400g,
35 min, 18°C) (36). Cells were resuspended in Dulbecco’s
minimal essential medium (DMEM, Gibco BRL, Burling-
ton, Ontario) and used immediately for cell migration
assays. Cell viability95% was demonstrated by trypan blue
exclusion. For membrane fluidity assays, cells were spun in
a Sorvall laboratory centrifuge (880 g, 25 min, room
temperature), and MCs were collected from the interface,
and washed three times in PBS (720 g, 10 min, 4°C). A
1-ml, platelet-free serum sample was collected and stored at
80°C for soluble CD14 (sCD14) measurements. Isolated
MCs were stained with Wright’s stain (Sigma, Oakville,
Ontario) and enumerated by hemocytometer.
Cell migration assay. Circulating MCs from normal do-
nors and patients with CAD were used to develop a
two-chamber mononuclear migration assay, based on the
original Boyden assay (36,37). Polycarbonate membranes in
transwell units (8-m pores; Costar, Atlanta, Georgia) were
coated with a 1:50 dilution of Matrigel:DMEM for 1 h in
5% CO2 at 37°C. Unbound Matrigel:DMEM was aspirated
and filters rinsed with PBS. A 1:50 dilution provided a
nonobstructing 0.1-mm-thick extracellular matrix protein
coating on the upper surface of the filter and the inside
margins of the pores as determined by electron microscopy
(not shown), stimulating connective tissue-induced cellular
migration through the membrane pores and onto the
underside of the filter. With lower dilutions of Matrigel,
monocytes did not penetrate the protein barrier. The same
lot of Matrigel was used for all assays to avoid variability in
Matrigel preparations. Next, 3  105 MCs in unsupple-
mented DMEM were added to the upper walls (36).
Chambers were incubated for 2 h at 37°C, 5% CO2. Media
and cells were then aspirated from the upper well, and
nonmigrating, adherent cells on the upper surface of the
membrane were removed by scraping the upper surface of
the filter with PBS rinsing.
Migrating MCs on the lower surface of the filter were
fixed for 15 min in 3% glutaraldehyde (Polysciences, War-
rington, Pennsylvania), incubated for 3 min in 0.5% Triton
X-100 (ICN Biochemicals, Aurora, Ohio (36). The MC
identification criteria included 12- to 20-m diameter, a
horseshoe-shaped, acentric, lighter staining nucleus (as
compared with lymphocytes), and a nucleus-to-cytoplasm
ratio 1.0 (Fig. 1A). Lymphocytes were smaller (12 m)
oval-shaped cells with small, darker-staining nuclei and
scant cytoplasm. The numbers of migrating monocytes and
lymphocytes were counted in three high-power fields for
each filter. Triplicate samples (filters) were assessed for each
cell isolate. To determine optimum incubation time, MCs
Abbreviations and Acronyms
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from donors with stable (3  105 MCs) were loaded in the
upper well and MC migration assessed from 5 min to 4 h.
Based on this preliminary experiment, subsequent migration
assays were run for 2 h.
Immunohistochemical identification of migrating mono-
cytes. Morphologic identification of monocytes was con-
firmed by immunohistologic staining for CD14 and by
independent blinded assessment by a pathologist (P.N.N.).
Filters were fixed in 0.1% glutaraldehyde in PBS (30 min)
and subsequently incubated with 0.3% H2O2 in methanol
(30 min). Filters were then washed three times in PBS for
5 min, blocked for 15 min in 10% normal horse serum in
PBS and incubated at 4°C overnight with mouse monoclo-
nal anti-human CD14 antibody (Caltag Laboratories, Bur-
lingame, California), diluted 1/100 in 0.1% bovine serum
albumin (BSA) in PBS and washed three times in 0.1%
BSA in PBS. Anti-isotypic, anti-rabbit IgG antibodies
(Sigma, Oakville, Ontario) diluted 1/100 in 0.1% BSA in
PBS and primary antibody-deficient samples served as
negative controls. Filters were then incubated with biotin-
ylated goat anti-mouse secondary antibody (Vector Labo-
ratories, Burlingame, California), diluted 1/50 for 1 h at
room temperature and washed in PBS; this was followed by
avidin-biotin complex amplification (Vectastain Elite, Vec-
tor Laboratories, Burlingame, California) (36) for 1 h at
room temperature. Colors were developed with liquid 3-3-
diaminobenzidine reagent (substrate). Membranes were
then counterstained for 30 s in Gill’s No. 2 Hematoxylin
Figure 1. (A) Immunostaining for CD14, a monocyte-specific marker, demonstrated migration of mononuclear cell (MC) isolated from patients with
unstable angina (UA) through a Matrigel-coated filter. (B) Bar graphs demonstrate a significant increase (p  0.05) in the mean migration rates of MCs
isolated from patients with UA on comparison with cells isolated from patients with stable angina or normal coronary arteries. No significant shifts in
migration rates were detected for lymphocytes. (C) A significant increase in cellular migration rates was detected after treatment with lipopolysaccharide
(LPS) for cells isolated from normal donors (p 0.001) but not for cells isolated from patients with unstable coronary artery disease. Relative MC migration
count was obtained by dividing MC cell counts at each LPS dose by untreated control counts. Results are presented as mean cell counts per high power
field of all donor samples within a category  SE. *p  0.05. AMI  acute myocardial infarction; CCS  Canadian Cardiovascular Society; L 
lymphocyte; M  monocyte; N  normal; P  pore; SA  stable angina.
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Solution (Sigma, Oakville, Ontario), rinsed and perma-
nently mounted on glass slides in Permount for light
microscopy.
Optical analysis (OA) of cellular membrane fluidity. For
OA of membrane fluidity (38) the ratio of pyrene excimer
(493 nm) to pyrene monomer (393 nm) fluorescence emis-
sion intensity (Iexc/Imon) after 325 nm excitation (Liconix
He/Cd laser, Santa Clara, California) was measured using
an Ocean Optics S2000 spectrophotometer attached to a
Power MacIntosh 9500/200 computer equipped with Spec-
tra Ware analysis software (Fig. 2). The rate of excimer
formation is a diffusion-controlled process proportional to
the pyrene molecular collision rate in cellular membranes
(28,32,38–40). The MCs were labeled with 4 mmol/l
pyrene dissolved in pure ethanol (Sigma, Missussauga,
Ontario) for 20 min at 37°C, with gentle shaking, and were
then washed twice to remove residual pyrene label. The
optimal time for loading pyrene (20 min) into purified MCs
was determined by time course (data not shown). A control
sample lacking MCs was also treated with pyrene, washed as
for the cell samples and tested for nonspecific pyrene
excimer formation in solution.
Monocyte stimulation. To ascertain whether increased
migration reflected an increased level of activation of circu-
lating MCs, the cells were pretreated with lipopolysaccha-
ride (LPS) for 30 min using blood from five normal donors
and two patients with unstable CAD (41) and cell migration
assessed as described. For functional response analyses using
the membrane fluidity assay, MCs were treated with either
saline control or activated with 2 U/ml human thrombin,
Figure 2. Membrane fluidity assays: A significant increase in membrane fluidity is evident in pyrene fluorescence emission spectra recorded from labeled
mononuclear cells (MC) after treatment with thrombin (A). Patients with unstable angina (UA) demonstrated a significantly altered membrane fluidity
profile (B) on comparison with cells obtained from normal individuals (p  0.01), patients with stable angina (p  0.001), and patients with acute
myocardial infarction (MI) (p  0.05). Thrombin treatment resulted in a significant change in the measured membrane fluidity of cells obtained from
normal individuals (p  0.05), but did not significantly alter the fluidity of cells obtained from patients with UA (C). Saline-treated cells (striped bars)
obtained from patients with UA show a similar profile to those thrombin-treated cells (black bars) obtained from normal individuals. Data represent the
mean Iexc/Imon ratios  SE. Cells were grouped according to the Canadian Cardiovascular Society guidelines. *p  0.05.
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100 ng/ml phorbol-12-myristate-13-acetate, or 107 mol/l
formyl-methionyl-leucyl-phenylalanine (fMLP) (activators
obtained from Sigma, Oakville, Ontario).
sCD14 measurements. The sCD14 was measured in se-
rum samples collected for membrane fluidity assay by
commercial sandwich-type ELISA (IBL, Hamburg, Ger-
many), using an oligoclonal capture antibody, followed by
an enzyme-tagged monoclonal detection antibody.
Statistics. Cellular migration (study 1) and membrane
fluidity (study 2) in each CCS category were compared by
Fisher-protected least significant difference multiple com-
parison (analysis of variance [ANOVA]). Mean migrating
cell counts were used for statistical analysis. Potential effects
of cardiac medications were assessed by ANOVA. Differ-
ences were considered significant at p  0.05.
RESULTS
Analysis of MC migration in patients. A 10-fold increase
in monocyte migration (Fig. 1) was detected in patients
with UA (CCS angina class IV) on comparison with normal
donors and a 3-fold increase in cell migration was detected
when compared to patients with stable angina (p  0.05)
(Fig. 1B). No differences were found, however, between
monocyte migration rates for cells isolated from normal
donors and patients with stable angina (p  0.497). Cells
obtained from patients with acute MI did not differ signif-
icantly in migration pattern from the other groups. A
twofold increase in cell migration rates was detected after
LPS stimulation of MCs from normal donors (Fig. 1C);
however, no increase was detected for cells from patients
with UA. Using the saline control as a baseline to calculate
relative migrating cell counts, significant differences were
detected with 10 ng and 100 ng LPS (p 0.001) (Fig. 1C).
No significant differences were detected for acute MI or
stable angina patients. No significant differences in lympho-
cyte migration rate was seen in CSS class I, II, III or IV
angina or acute MI patients (Fig. 1B). Negative controls
consisting of an irrelevant rabbit, anti-isotypic IgG antibody
control and primary antibody deficient incubation did not
stain positively. Lymphocytic cells did not stain with anti-
CD14 antibody.
Membrane fluidity assay. Generalized MC activation
states were also assessed by membrane fluidity assay for
normal individuals and patients with CAD. Figure 2A
illustrates a typical pyrene spectrum before and after treat-
ment with the activator thrombin. Significant increases in
baseline membrane fluidity (Iexc/Imon) were detected in cells
obtained from patients with UA (CCS angina class IV)
when compared to cells from normal individuals or patients
with stable angina (p  0.01 and p  0.001, respectively;
Fig. 2B). Membrane fluidity values for MCs isolated from
UA patients were also distinguished readily from cells taken
from patients with acute MI (p  0.05; Fig. 2B). No
significant correlation was observed between Iexc/Imon ratio
values and the last time recorded for chest pain for patients
with stable or unstable angina (p 0.5436). However, there
was a trend toward an increase in membrane fluidity; for
monocytes taken from a patient with pain within 24 h of
admission, membrane fluidity was 1.271  0.429 and for
patients with pain more than 24 h prior to monocyte
isolation membrane fluidity was 0.984  0.185.
Treatment of MCs obtained from normal individuals
with thrombin produced a statistically significant (p 0.05)
increase in membrane fluidity (Iexc/Imon) corresponding to
the same profile observed in untreated cells obtained from
patients with UA (Fig. 2A, C). In addition, application of
thrombin to cells obtained from UA patients did not result
in any additional change in membrane fluidity. Both PMA
and fMLP significantly reduced Iexc/Imon in MCs from
normal donors (by 45% and 29% compared to untreated
MCs; p  0.05), whereas changes in membrane fluidity in
cells from patients with documented ischemic heart disease
(IHD) were statistically significant only in the case of fMLP
(a reduction of 35%; p  0.05). Very little difference (15%;
NS) was found in the baseline membrane fluidity value
between patients with IHD and normal blood donors.
sCD14 measurements. A significant increase (p 0.01) in
levels of circulating sCD14 in the blood samples from
patients with type IV UA was detected when compared to
normal individuals and patients with acute MI (p  0.01).
Figure 3 demonstrates a 41% higher level of sCD14 in
plasma obtained from patients with UA when compared to
normal individuals and 48% higher levels than individuals
with acute MI (5.9  0.6 g/ml vs. 3.5  0.26 g/ml and
3.1  0.2 g/ml, respectively). Soluble CD14 levels in stable
Figure 3. Significant increases in serum levels of soluble CD14 (sCD14)
(p  0.01) were found in patients with unstable coronary artery disease as
compared to normal donors and patients with acute myocardial infarction
(MI). The level of sCD14 did not differ significantly from individuals with
stable angina (p  0.06), but did show a trend toward an increase. Data
represent the mean level of sCD14 expressed in g/ml; error bars represent
SE. UA  unstable angina.
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angina patients showed a trend toward an increase that did
not reach statistical significance (p  0.066).
Analysis of monocyte activation and cardiovascular med-
ications. Potential medication-related effects on mononu-
clear cell migration and membrane fluidity were assessed
and analyzed by ANOVA. Both monocyte and lymphocyte
cell migrations did not correlate with any of the cardiac
medications used (p  0.313), nor did membrane fluidity
values (p  0.075), indicating that the observed changes in
cell migration and membrane fluidity are not related to the
use of cardiac medication in unstable coronary syndrome.
The medications assessed were acetylsalicylic acid, other
antiplatelet drugs (ticlopidine, clopidogrel, and abciximab),
nitroglycerin, heparin and derivatives, beta-andrenergic re-
ceptor blockers, angiotensin-converting enzyme inhibitors,
HMG-CoA reductase inhibitors (statins), calcium channel
blockers and parasympatholytics.
DISCUSSION
We have assessed circulating MC activation in the periph-
eral blood of patients with UA using an assay of cellular
invasive capacity in Boyden chambers and an OA assay of
membrane fluidity. An increased baseline level of monocyte
activation was detected in the circulation of patients with
UA, but not in patients with stable angina or acute MI.
These assays allow direct evaluation of monocytic cell
function by measuring the migratory response of cells
exposed to matrix proteins in the absence of additional
chemotactic factors. Only previously activated cells are
expected to migrate in this assay. The significantly increased
migration rates of monocytes from patients with UA sup-
port an increase in monocyte inflammatory responses during
plaque destabilization and UA development, complement-
ing serum-based markers. We postulate that the increased
rate of migration might be produced by “priming” of
circulating monocytes by a chronic inflammatory state
initiated at sites of plaque instability. These results support
our hypothesis that cells isolated from patients with UA are
functionally altered and already activated in the peripheral
circulation, making them refractory to further stimulation
(Figs. 1 and 2).
Optical analysis. Significantly increased baseline mem-
brane fluidity in MC from UA patients was consistent with
altered baseline activation states. The lack of changes in
membrane fluidity upon activation treatment in MCs from
UA patients, but not normal volunteers, acute MI or stable
angina patients, further supports an altered baseline cellular
activation (Fig. 2). Changes in membrane fluidity (either an
increase or a decrease) are associated with cellular activation
in response to effector functions as the cell consolidates its
surface components, rearranges its cytoskeleton, and acti-
vates signal transduction pathways. Exposure to large, mul-
tifunctional proteins such as thrombin can also result in an
increase in membrane fluidity (39,40). Increased activation
may be represented by a need for increased cell mobility and
migration. Although several cell types have been demon-
strated to alter membrane fluidity in response to activation,
ours is the first report of application of a membrane fluidity
assay for analysis of circulating human MCs. Untreated cells
obtained from patients with UA had membrane fluidity
profiles very similar to thrombin-treated cells obtained from
normal individuals, and they were not altered after thrombin
treatment, again indicating that these cells were already
maximally activated (Fig. 2).
Elevated markers of inflammation in patients with un-
stable angina. It is notable that the observed differences in
migratory capacity and membrane fluidity were confined to
patients with UA and not patients with acute MI. Increases
in inflammatory markers in patients with UA when com-
pared to acute MI have been previously reported (12,42). In
1994, Jude et al. (12) found that patients with UA exhibited
higher levels of tissue factor expression in MCs than did
patients with stable angina, whereas no difference in this
parameter was found for patients with acute MI and stable
angina. In 1999, Liuzzo et al. (42) observed consistently
higher levels of CRP and SAA in patients with UA when
compared to patients with totally unheralded MI. Further,
significant differences between the IL-6 levels in blood
plasma of patients with UA and acute MI have been
reported by Manten et al. (43). These studies suggest that
these two clinical presentations may be related to different
pathogenic components of acute coronary occlusion and are
consistent with our findings.
Elevated sCD14 in UA patients. Patients with UA in this
study had detectable increases in plasma CD14 (sCD14)
levels, a serum marker for activated monocytes, supporting
increased MC activation. A membrane-anchored glycopro-
tein, CD14 is involved in adhesion to the endothelium and
also the receptor for LPS (44,45). Stimulation of CD14
(either by LPS or released sCD14 molecules) results in the
secretion of tumor necrosis factor, interferon and other
proinflammatory cytokines (44,45). One study has demon-
strated elevated sCD14 in patients with noninfectious,
inflammatory diseases such as rheumatoid vasculitis and
systemic lupus erythematosus, reflecting a generalized acti-
vation of circulating monocytes (44,45). A genetic polymor-
phism in the CD14 promoter region has also been identified
as a possible risk factor for MI (46–48). This is the first
genetic factor, barring conventional factors, associated with
MI risk, linked to monocyte function, and might be an early
clinical marker for progression to plaque instability. Unsta-
ble plaque development is a dynamic process whereby
inflammatory and immune system cells become activated
and further contribute to the pathogenetic sequelae. Our
results support the conclusion that it is not the critical mass
of atherosclerotic disease, but rather the extent of plaque
instability with invading activated macrophages (49), that is
necessary to induce a systemic increase in the level of
activation of circulating monocytes. Assays designed to
evaluate the state of circulating monocyte activation may
prove beneficial in preventative diagnoses.
1345JACC Vol. 38, No. 5, 2001 Zalai et al.
November 1, 2001:1340–7 Monocyte Activation in Unstable Coronary Syndromes
Study limitations. T-CELL ACTIVATION IN UA PATIENTS.
The present study does not rule out lymphocyte activation
in addition to monocyte function. Our results are consistent
with a limited T-lymphocyte activation profile, as has been
reported for TH1-T-cells (50). The presence of enhanced
MC invasion without concomitant accelerated lymphocyte
migration in the Boyden chamber assay would, however,
argue that the observed alterations in membrane fluidity
reflect MC activation. This study also does not conclusively
distinguish, but instead raises, the following questions: 1)
Are monocytes activated secondary to the presence of
unstable plaque? 2) Conversely, do activated monocytes
contribute to the development of UA? It is probable that
both processes are present and equally contribute to insta-
bility.
Conclusions. In these studies we have: 1) evaluated the
migration rates of MCs isolated from the peripheral circu-
lating blood, and 2) assessed the membrane fluidity of MCs
as a marker of cellular activation in patients with differing
extents of CAD. In patients with UA, but not in patients
with stable angina or acute MI, increased spontaneous
migration of monocytes and MC membrane fluidity were
detected. Patients with UA also demonstrated increased
levels of the monocyte-specific activation marker sCD14.
Taken together, these results support the hypothesis that
activated monocytes are present and detectable in the
circulating blood of patients with UA, and they are likely
associated with an upregulated inflammatory state initiated
at sites of plaque rupture. Furthermore, these experiments
provide a novel diagnostic tool for exploring cellular activa-
tion directly.
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